Developing a Functional Cure for Crohn's Disease

Revolutionary CRISPR gene editing technology designed for one-time treatment, targeting the genetic foundations of disease rather than managing symptoms

Our Scientific Approach

Advanced CRISPR editing technology with proprietary delivery systems, designed for safety and lasting efficacy

Advanced CRISPR Editing Technology

Next-generation gene editing tools engineered for precision targeting of disease-causing genetic variants with enhanced safety profiles.

Novel Delivery Systems

Proprietary delivery mechanisms specifically designed for gastrointestinal targeting, ensuring therapeutic molecules reach the right cells.

Safety & Efficacy Focus

Rigorous safety protocols and efficacy validation, following international gene therapy guidelines with comprehensive risk assessment.

Proprietary Genetic Targeting

Our approach addresses key genetic factors in disease pathogenesis, targeting root causes rather than downstream effects.

One-Time Treatment Vision

Unlike current therapies that require lifelong management, our approach is designed to provide lasting therapeutic benefit through a single treatment course.

By addressing the genetic foundations of Crohn's disease, we aim to restore normal cellular function and provide patients with a functional cure, not just symptom relief.

Development Pipeline

Strategic roadmap from pre-clinical research to clinical application

Current Stage

Foundational Development

Foundational stage focusing on initial research and concept development. Establishing scientific framework and seeking pre-seed funding to advance toward pre-clinical development phase.

2026 - Post Pre-Seed

Pre-Clinical Development

Begin active development and validation of our proprietary gene editing approach. Optimizing delivery systems and conducting comprehensive safety assessments in laboratory models.

2027-2028

Regulatory Pathway & Manufacturing

Engaging with MHRA and FDA to establish clear regulatory pathways. Establishing strategic partnerships with leading GMP manufacturing facilities and preparing comprehensive documentation following gene therapy guidelines.

2028+

First-in-Human Trials

Planned progression to Phase I clinical trials to evaluate safety and preliminary efficacy. Careful patient selection and comprehensive monitoring protocols following established clinical trial frameworks.

Why It Matters

The transformative impact of a functional cure for Crohn's disease

3.8M
People with Crohn's globally
$10B
Annual treatment costs
70%
Reduced quality of life
1st
Functional cure approach

Patient Impact

Patients currently face lifelong medication regimens with significant side effects. A functional cure would restore normal life quality and eliminate the burden of chronic disease management.

Quality of Life Improvements

Freedom from daily medications, reduced hospitalizations, and return to normal activities. Patients could focus on living their lives rather than managing their disease.

Healthcare System Benefits

Significant reduction in long-term healthcare costs, decreased hospital admissions, and reduced burden on healthcare resources through prevention of disease progression.

Economic Impact

A functional cure represents massive economic value through reduced lifetime treatment costs, increased productivity, and elimination of chronic care requirements.

Scientific Excellence

Rigorous development following international standards

Full methodology available under NDA
Following FDA/EMA gene therapy guidelines
UK-incorporated, MHRA-compliant development
Building world-class scientific advisory board
Comprehensive pre-clinical validation
Rigorous safety and efficacy protocols

Partnership Opportunities

We welcome collaborations with leading research institutions, clinical partners, and investors who share our vision of developing breakthrough therapies for Crohn's disease.